BRCA2 and prostate carcinoma: In view of the above evidence and the nature of the patient’s germline BRCA2 mutation, we sought and obtained emergency FDA approval for talazoparib, an oral PARP inhibitor approved for germline BRCA2-mutated breast and prostate cancers.